68Ga-PSMA-PET/CT显像用于局限期原发性前列腺癌患者的调强放疗计划设计并整合推量
21例既往未接受局部治疗的前列腺癌患者(平均70岁)接受68Ga-PSMA-PET/CT显像,以病灶最大摄取活度的40%为阈值分割PET活性体积,为每例患者计算五种放疗计划变体,并用QUANTEC生物学模型分析肿瘤控制概率与正常组织并发症概率。与常规计划相比,整合推量及仅照射PET阳性体积的计划均使肿瘤控制概率升高(均p<0.0001),整合推量80 Gy时直肠中位正常组织并发症概率显著增加,其余计划直肠与膀胱正常组织并发症概率无统计学显著增加。作者认为该影像信息可实现更个体化的前列腺放疗计划设计,但需进一步研究明确临床获益。
要点
- 21例局限期原发性前列腺癌患者行68Ga-PSMA-PET/CT显像并以最大摄取活度40%为阈值分割PET活性体积。
- 整合推量75.6 Gy与80 Gy及仅照射PET阳性体积75 Gy与95 Gy的计划肿瘤控制概率均较常规计划升高(均p<0.0001)。
- 整合推量80 Gy时直肠中位正常组织并发症概率显著增加,其余计划直肠与膀胱正常组织并发症概率无统计学显著增加。
核心结论
- 使用68Ga-PSMA-PET/CT影像信息可实现更个体化的前列腺放疗计划设计。
- 所识别的活性肿瘤体积的肿瘤控制概率升高,而直肠与膀胱的正常组织并发症概率保持不变或更低。
- 作者指出需进一步研究明确这些技术对患者的临床获益。
研究设计与样本
- 研究纳入21例既往未接受局部治疗的前列腺癌患者,平均年龄70岁,接受68Ga-PSMA-PET/CT显像。
- 在获得的数据集上手动勾画危及器官和标准前列腺靶体积。
- 以病灶最大摄取活度的40%为阈值分割PET活性体积(PTV_PET),随后手动调整。
- 为每例患者计算五种不同的放疗计划变体。
- 使用院内开发软件按QUANTEC分析所生成的治疗计划,并计算所有计划变体的肿瘤控制概率(TCP)和正常组织并发症概率(NTCP)。
主要发现
- 与常规计划相比,整合推量75.6 Gy的肿瘤控制概率为(95.2 ± 0.5%),整合推量80 Gy为(98.1 ± 0.3%),仅照射PET阳性体积75 Gy为(94.7 ± 0.8%),仅照射PET阳性体积95 Gy为(99.4 ± 0.1%)(均p < 0.0001)。
- 整合推量80 Gy时发现直肠中位正常组织并发症概率显著增加。
- 其余所有计划中,直肠与膀胱的正常组织并发症概率均未发现统计学显著增加。
关键数值与推荐
- PET活性体积分割阈值:病灶最大摄取活度的40%,随后手动调整。
- 计划变体肿瘤控制概率:整合推量75.6 Gy为(95.2 ± 0.5%),整合推量80 Gy为(98.1 ± 0.3%),仅照射PET阳性体积75 Gy为(94.7 ± 0.8%),仅照射PET阳性体积95 Gy为(99.4 ± 0.1%)(均p < 0.0001)。
- 整合推量80 Gy时直肠中位正常组织并发症概率显著增加;其余计划直肠与膀胱正常组织并发症概率无统计学显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究明确这些技术对患者的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of our study was to show the feasibility and potential benefits of using 68Ga-PSMA-PET/CT imaging for radiation therapy treatment planning of patients with primary prostate cancer using either integrated boost on the PET-positive volume or localized treatment of the PET-positive volume. The potential gain of such an approach, the improvement of tumor control, and reduction of the dose to organs-at-risk at the same time was analyzed using the QUANTEC biological model. METHODS: Twenty-one prostate cancer patients (70 years average) without previous local therapy received 68Ga-PSMA-PET/CT imaging. Organs-at-risk and standard prostate target volumes were manually defined on the obtained datasets. A PET active volume (PTV_PET) was segmented with a 40% of the maximum activity uptake in the lesion as threshold followed by manual adaption. Five different treatment plan variations were calculated for each patient. Analysis of derived treatment plans was done according to QUANTEC with in-house developed software. Tumor control probability (TCP) and normal tissue complication probability (NTCP) was calculated for all plan variations. RESULTS: Comparing the conventional plans to the plans with integrated boost and plans just treating the PET-positive tumor volume, we found that TCP increased to (95.2 ± 0.5%) for an integrated boost with 75.6 Gy, (98.1 ± 0.3%) for an integrated boost with 80 Gy, (94.7 ± 0.8%) for treatment of PET-positive volume with 75 Gy, and to (99.4 ± 0.1%) for treating PET-positive volume with 95 Gy (all p < 0.0001). For the integrated boost with 80 Gy, a significant increase of the median NTCP of the rectum was found, for all other plans no statistical significant increase in the NTCP neither of the rectum nor the bladder was found. CONCLUSIONS: Our study demonstrates that the use of 68Ga-PSMA-PET/CT image information allows for more individualized prostate treatment planning. TCP values of identified active tumor volumes were increased, while rectum and bladder NTCP values either remained the same or were even lower. However, further studies need to clarify the clinical benefit for the patients applying these techniques.
引用
- Thomas L, Kantz S, Hung A, et al. 68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging. 2018. PMID: 29468311. doi:10.1007/s00259-018-3954-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。